IBA Expands Radiopharmaceutical Reach with ARTMS QIS Distribution…

Event summary

IBA will distribute ARTMS’s QUANTM® Irradiation System (QIS®) to cyclotron users worldwide, effective October 1, 2026.
QIS® is the only solid-target cyclotron technology in the U.S. with validated gallium-68 (⁶⁸Ga) and zirconium-89 (89Zr) production.
The partnership aims to accelerate theranostics expansion by enabling decentralized, high-yield radiometal production.
IBA will offer QIS® to new and existing cyclotron customers, simplifying sourcing, installation, and servicing through a single supplier.

The big picture

The deal underscores the growing strategic importance of theranostics in precision oncology, as IBA and Telix aim to create a more integrated radiopharmaceutical ecosystem. By combining IBA’s expertise in particle acceleration with ARTMS’s solid-target technology, the partnership addresses the critical need for scalable, decentralized production of radiometals to support the expanding theranostics market. This collaboration is part of a broader industry trend toward consolidating radiopharmaceutical supply chains to improve accessibility and reliability for healthcare providers.

What we're watching

Market Penetration: How IBA’s global reach will impact the adoption of QIS® in regions with limited access to advanced radiopharmaceutical production technologies.
Technological Integration: Whether the seamless integration of QIS® with IBA’s cyclotron platforms will drive operational efficiencies and cost savings for healthcare providers.
Regulatory Dynamics: The pace at which regulatory approvals for new radiometals, such as technetium-99m (99mTc) and copper-64 (64Cu), will advance under this partnership.